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RemodellingPhosphorylation and inactivation of glycogen synthase kinase 3 (GSK-3) is observed in the failing heart
induced by chronic pharmacological stress and aortic banding. Constitutive kinase activity attenuates
pathological remodelling, suggesting an obligatory role in stress signalling. However, this has been
challenged by recent data whereby conditional GSK-3β deletion has been shown to protect against post-
infarct remodelling. Here, we set out to determine the chronic remodelling response to infarction in hearts of
GSK-3α/βAla21/9 knockin (KI) mice encoding constitutively active GSK-3 isoforms. At 4 weeks after infarction
there were signiﬁcant increases in normalised heart weight and left ventricular (LV) muscle volume
compared to sham in both KI and wild type animals. This was associated with an increase in LV cavity
dimensions and remote LV wall thickness. Hypertrophy in both genotypes resulted in marked contractile
impairment on both invasive and non-invasive interrogation. Increased phosphorylation of GSK-3β, but not
GSK-3α, was demonstrated at 1 week after infarction and remained elevated at 4 weeks compared to sham-
treated hearts. In conclusion, GSK-3β phosphorylation and inactivation occurs with, but is not an obligatory
signalling event in, chronic post-infarct remodelling in the mouse heart. This highlights the heterogeneity of
pathological hypertrophy and the divergent role of GSK-3 signalling in chronic myocardial stress.’Hospital, London SE1 7EH, UK.
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Glycogen synthase kinase-3 (GSK-3) signalling is implicated in
pathological stress remodelling in theheart. Two isoformsare expressed
equally within cardiomyocytes, GSK-3α and GSK-3β, but it is inactiva-
tion of the latter through N-terminal Ser9-phosphorylation which is
considered crucial in pathological hypertrophy. GSK-3β phosphoryla-
tion is demonstrated with aortic banding or treatment with pro-
hypertrophic agonists such as isoproterenol, phenylephrine and
endothelin-1 [1–3]. Conversely, hypertrophy induced by these inter-
ventions is attenuated throughexpressionof inactivation-resistantGSK-
3βAla9 or overexpression of wild-type GSK-3βSer9 isoforms [1–4].
Chronic remodelling after regional infarction shares many of the
pathological traits induced by other experimental hypertrophy proto-
cols, including cardiomyocyte hypertrophy, interstitial ﬁbrosis and
foetal gene reactivation [5,6]. Infarction is the predominant substrate for
heart failure in clinical practice [7], and arguably represents a more
pathophysiologically relevant platform for study, despite its relative
complexity. Towhat extent common signalling pathways exist between
these models, however, is unclear. In particular, there is a relative
paucity of data regardingGSK-3 activity,with aparadoxical bias towards
the clinical literature. Human tissueobtained at transplantation or at thetime of ventricular assist device implantation for end-stage heart failure,
for example, conﬁrms increased GSK-3β phosphorylation, but a more
heterogeneous signalling response to mechanical off-loading [8,9].
Recently, data have been published in a mouse with inducible
cardiomyocyte-speciﬁc GSK-3β deletion (conditional knockout) [10].
Eight weeks after permanent ligation of the proximal left anterior
descending artery, KO hearts demonstrated exaggerated hypertrophy,
associatedwith a paradoxical attenuation in ventricular dilatation and
contractile dysfunction. Examination of remote myocardium con-
ﬁrmed a proliferative cardiomyocyte response with hypertrophy and
a reduction in apoptosis [10]. Paradoxically therefore, pathological
remodelling in this settingmay be attenuated by the absence of GSK-3
kinase activity.
In order to clarify the role of GSK-3, we set out to examine post-
infarction remodelling in GSK-3α/βAla21/9 knockin (KI) mice expres-
sing constitutively active forms of the kinase within the heart.
2. Methods
2.1. GSK-3α/βAla21/9 KI mice
KI mice were kindly provided by Professor Alessi (University of
Dundee, UK). The targeting strategy and consequent effect on PKB/
Akt-GSK3-GS signalling axis have been described previously [1,11,12].
All experiments were performed in accordance with UK Home Ofﬁce
regulations.
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Experiments were undertaken in weight-matched (25–30 g) adult
male mice. Animals were subjected to permanent left anterior
descending (LAD) artery ligation or sham procedure, as previously
described [13]. Risk area was determined by intravenous delivery of
Evan's blue solution (0.5 ml, 2%). Hearts were then explanted, ﬁxed
(10% paraformaldehyde) and sectioned (700 μm) for planimetry, as
described [1,13].
2.3. Cardiac remodelling
In recovery experiments, hearts of surviving mice were examined
at 4 weeks after LAD ligation or sham procedure by echocardiography,
pressure-volume interrogation and morphometry of explanted
hearts, as described [1,13]. Infarct size was calculated morphologically
as the mean percentage scar circumference relative to total LV
circumference across all heart cross-sections.
2.4. Protein chemistry
In parallel experiments inWT animals, hearts were rapidly excised
at set time points after surgery for protein interrogation. Total and
phosphoserine-Ser21/9 levels of GSK-3 were estimated by SDS-PAGE
and western blotting of whole heart homogenates, as previously
described [1,12]. Insulin-treated hearts were used as positive controls
for GSK-3 inactivation, as previously [1,12].
2.5. Statistics
Data are presented as means ± SEM. Scatter plot data were
subjected to linear regression analysis. Survival was analysed by the
Kaplan–Meier method with a log-rank test for differences between
groups. Comparisons between groups were assessed for signiﬁcance
by one-way or two-way analysis of variance (ANOVA), as appropriate.
When signiﬁcant differences were detected, individual mean values
were compared by Bonferroni's post hoc test. A P-value less than 0.05
was considered signiﬁcant.
3. Results
3.1. Determination of risk area
Initial experiments set out to exclude potential bias effects of
variant epicardial coronary anatomy between genotypes. Reassuring-
ly, no differences in area at risk (AAR) were detectable between KI,
WT or outbred C57BL/6 mice (AAR 45.4±6.8%, 40.3±5.1% and
39.6±3.4%, respectively, n=8/group, p=ns) (Fig. 1A).
3.2. Survival and GSK-3α/β phosphorylation after MI
Survival rates after infarction were identical between genotypes
(Fig. 1B) despite heart homogenates inWT animals revealing inactivat-
ing phosphorylation of GSK-3β, but not GSK-3α, at the end of the ﬁrst
and fourth post-operative weeks (Fig. 1D).
3.3. Chronic ventricular remodelling
Morphological assessment of WT hearts at 4 weeks after surgery
conﬁrmed signiﬁcant hypertrophy in infarct- vs. sham-treated
animals, with increases in normalised heart weight (HW/BW 7.5±
0.5 vs. 5.3±0.3 mg/g, n=6/group, pb0.05) and calculated left
ventricular muscle volume (LVV 169.2±21.9 vs. 99.9±7.1 μl3,
n=6/group, pb0.05) (Table 1). Mean LV measurements taken from
700 μm-thick sections at the mid-level of the papillary muscle
conﬁrmed scar thinning (317±56 vs. 1275±62 μm sham, pb0.05)and remote hypertrophy of viable myocardium (1810±87 vs. 1327±
64 μm, pb0.05) (Table 1). Infarct remodelling at 4 weeks was
associated with signiﬁcant ventricular dilatation and impairment of
contractility, both from invasive and non-invasive interrogation
(Table 1, Fig. 1E). Importantly, hearts of KI animals demonstrated
similar infarct sizes (Table 1, Fig. 1C), morphological and physiological
changes following LAD ligation, without evidence of protection or,
conversely, potentiation of injury and pathological remodelling.
4. Discussion
The major ﬁnding of this study is that constitutive GSK-3α/β
activity is unable to prevent chronic stress remodelling in murine
hearts following regional infarction. This contrasts directly with
protection against chronic β-adrenergic stimulation or pressure-
overload demonstrated previously using this genetic approach [1,2].
Together, these data highlight the mechanistic heterogeneity of
pathological hypertrophy, and the likely redundancy of GSK-3 in
more complex models.
As a direct inhibitory regulator of a number of key transcription and
translational processes, GSK-3 is proposed to be a strategic point of
signalling integration in both developmental cardiac growth and
pathological remodeling. Attention has largely focused on GSK-3β,
with expression of inactivation-resistant isoforms robustly protective
against both pharmacological and pressure-induced hypertrophy [1–4].
GSK-3α activity may counterbalance some of these beneﬁcial effects
during pathological growth, with enhanced ﬁbrosis and blunted
cardiomyocte proliferation [2,14]. However the biological signiﬁcance
of this remains unclear, since targeted studies in isoform-speciﬁc and
dual isoform knockin mice suggest phenotype-dominance of the GSK-
3β isoform during stress [2].
The recent demonstration that inducible GSK-3β deletion protects
murine hearts from chronic remodelling after myocardial infarction,
questions the obligatory role of GSK-3β inactivation in pathological
hypertrophy and highlights the likely model-dependence of this
process [10]. However, GSK-3 function may extend beyond that of its
kinase activity, since it can act to coordinate protein complexes which
maybe relevant to cell death [15]. Hence conditional knockout and
constitutively-active knockin mice are not antitheses. Furthermore,
using the same mouse line we have previously shown that
pathological hypertrophy in response to isoproterenol is attenuated
[1]. Together with the ﬁndings here, this suggests that the role of GSK-
3 may differ by physiological stress, in keeping with ﬁndings in the
GSK-3β cardiomyocyte speciﬁc conditional KO mouse [10].
Accepted limitations of our genetic model include potential non-
selective cellular consequences distinct from Ser21/9 mutation, and
unexpected systemic responses with ubiquitous mutant kinase
expression. Experiments in isoform-speciﬁc KI animals were not
performed, since double KI animals revealed no overt stress-
phenotype compared to WT, but this limitation is also acknowledged.
In summary, although GSK-3β phosphorylation occurs in the failing
mouse heart after regional infarction, GSK-3β inactivation does not
appear to be an obligatory signalling event in pathological remodelling.
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Fig. 1. LAD ligation experiments. (A) Area at risk (AAR) distal to the LAD ligature was determined in wild type (WT), knockin (KI) and outbred C57BL/6 mice by Evan's Blue staining
(0.5 ml, 2%) and planimetry of sectioned (700 μm) hearts. (B) In recovery experiments, no differencewas seen in survival between genotypes following infarction. (C) Representative
examples of heart cross-sections (700 μm) at 4 weeks after myocardial infarction (MI) or sham procedure. (D) Representative immunoblots of phosphorylated and total GSK-3 protein
levels in WT heart homogenates taken at 1 day, 1 week and 1 month after LAD ligation (MI) or sham. Insulin-treated hearts are used as positive controls for GSK-3 phosphorylation.
Quantitative data for GSK-3β phosphorylation are also shown as a ratio of phospho/total protein and represent the mean±SEM of 4 independent experiments, *pb0.05 vs. sham at
indicated time points. (E) Echocardiography was performed at 4-weeks under isoﬂurane anaesthesia (1–2%). FS=fractional shortening, LVIDd/s=left ventricular internal dimension
(diastole/systole). N=8/group, * pb0.05 vs. sham.
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Table 1
Morphology and pressure–volume interrogation. Hearts were subjected to P-V interrogation under isoﬂurane anaesthesia 4 weeks after infarction or sham procedure. Morphometry
was performed on ﬁxed heart sections (700 μm) at the level of the mid-papillary muscle. N=6/group, *pb0.05 vs sham (within genotype). HR=heart rate, SV=stroke volume,
CO=cardiac output, EF=ejection fraction, dP/dt(MAX)=maximum ﬁrst derivative of pressure, dP/dt(MIN)=minimum ﬁrst derivative of pressure, ESP=end-systolic pressure,
ESV=end-systolic volume, Ea=arterial elastance, SW=stroke work, EDP=end-diastolic pressure, EDV=end-diastolic volume, τ(Weiss)=isovolumic time constant of relaxation.
WT KI
Sham MI Sham MI
Morphology
HW/BW (mg/g) 5.3±0.3 7.5±0.5* 5.9±0.4 7.8±0.6*
LV muscle volume (μl3) 99.9±7.1 169.2±21.9* 119.1±5.7 180±19.0*
LW/BW (mg/g) 6.9±0.5 8.4±1.1 6.8±0.7 9.7±0.8
Scar thickness (μm) 1275±62 317±56* 1300±62 293±92*
Remote LV thickness (μm) 1327±64 1810±87* 1362±44 1633±63*
Infarct size (% of LV circumference) N/A 37±6 N/A 41±9
P-V Analysis
Systole
HR (bpm) 634±12 587±10 610±17 608±21
SV (μl) 16.9±1.0 13±1.1* 15.9±0.6 12.9±1.2
CO (ml/min) 10.7±0.6 7.7±0.4* 9.7±0.4 7.7±0.6
EF (%) 69±3 37±4* 74±4 44±4*
dP/dtMAX (mm Hg/s) 6824±309 5531±483 6464±272 5978±550
ESP (mm Hg) 86.8±2.2 86.2±6.0 85.8±2.4 91.8±4.4
ESV (μl) 7.6±0.8 22.8±2.0* 6.0±1.1 16.6±2.0*
SW 801±70 548±74 709±74 497±84
Ea (mm Hg/μl) 5.4±0.4 7.3±0.8 6.1±0.4 7.7±0.9
Diastole
dP/dtMIN (mm Hg/s) -3306±340 -2935±791 -2956±220 -3349±548
EDP (mm Hg) 8.0±0.4 11.7±1.1* 8.3±0.4 12.9±1.7*
EDV (μl) 24.5±1.6 35.8±2.1* 21.9±1.4 29.4±2.4*
Τ (Weiss) (ms) 6.2±0.2 8.2±0.3* 6.4±0.2 8.4±0.7*
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